Literature DB >> 28315846

Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative.

Dominic H Ffytche1,2, Joana B Pereira3, Clive Ballard1,4, K Ray Chaudhuri1,5, Daniel Weintraub1,6,7,8, Dag Aarsland1,2,9.   

Abstract

BACKGROUND: Parkinson's Disease (PD) psychosis refers to the spectrum of illusions, formed hallucinations and delusions that occur in PD. Visual hallucinations and illusions are thought to be caused by specific cognitive and higher visual function deficits and patients who develop such symptoms early in the disease course have greater rates of cognitive decline and progression to dementia. To date, no studies have investigated whether such deficits are found prior to the onset of PD psychosis.
METHOD: Here we compare baseline cognitive, biomarker (structural imaging and cerebrospinal fluid) and other PD psychosis risk factor data in patients who go on to develop illusions or hallucinations within 3-4 years of follow-up in the Parkinson's Progression Markers Initiative cohort of newly diagnosed PD.
RESULTS: Of n=423 patients with PD, n=115 (27%) reported predominantly illusions with the median time of onset at 19.5 months follow-up. At study entry these patients had reduced CSF amyloid Aß1-42, lower olfaction scores, higher depression scores and increased REM sleep behaviour disorder symptoms compared to patients without early onset PD psychosis but no differences in cognitive, higher visual or structural imaging measures. A subset of patients with early onset formed hallucinations (n=21) had reduced higher visual function at baseline, cortical thinning in parietal, occipital and frontal cortex and reduced hippocampal volume.
CONCLUSIONS: The findings suggest early onset illusions and formed hallucinations are linked to amyloid pathology in PD and point to a difference in the underlying pathophysiological mechanism of illusions and formed hallucinations, with implications for their respective links to future cognitive decline. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28315846      PMCID: PMC5362125          DOI: 10.1136/jnnp-2016-314832

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  41 in total

Review 1.  Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines.

Authors:  Irene Litvan; Jennifer G Goldman; Alexander I Tröster; Ben A Schmand; Daniel Weintraub; Ronald C Petersen; Brit Mollenhauer; Charles H Adler; Karen Marder; Caroline H Williams-Gray; Dag Aarsland; Jaime Kulisevsky; Maria C Rodriguez-Oroz; David J Burn; Roger A Barker; Murat Emre
Journal:  Mov Disord       Date:  2012-01-24       Impact factor: 10.338

2.  Visual misperceptions and hallucinations in Parkinson's disease: dysfunction of attentional control networks?

Authors:  James M Shine; Glenda M Halliday; Sharon L Naismith; Simon J G Lewis
Journal:  Mov Disord       Date:  2011-09-23       Impact factor: 10.338

3.  Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression.

Authors:  Letterio Morgante; Carlo Colosimo; Angelo Antonini; Roberto Marconi; Giuseppe Meco; Massimo Pederzoli; Francesco E Pontieri; Giulio Cicarelli; Giovanni Abbruzzese; Salvatore Zappulla; Silvia Ramat; Michela Manfredi; Edo Bottacchi; Michele Abrignani; Alfredo Berardelli; Autilia Cozzolino; Claudio Paradiso; Danilo De Gaspari; Francesca Morgante; Paolo Barone
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-08-11       Impact factor: 10.154

4.  Olfactory impairment predicts cognitive decline in early Parkinson's disease.

Authors:  Michelle E Fullard; Baochan Tran; Lama M Chahine; James F Morley; Sharon X Xie; Jon B Toledo; Christi Scordia; Carly Linder; Rachael Purri; Daniel Weintraub; John E Duda
Journal:  Parkinsonism Relat Disord       Date:  2016-02-19       Impact factor: 4.891

Review 5.  Structural and functional neuroimaging in patients with Parkinson's disease and visual hallucinations: A critical review.

Authors:  Abhishek Lenka; Ketan Ramakant Jhunjhunwala; Jitender Saini; Pramod Kumar Pal
Journal:  Parkinsonism Relat Disord       Date:  2015-04-17       Impact factor: 4.891

6.  Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease.

Authors:  Gisela Llebaria; Javier Pagonabarraga; Mercè Martínez-Corral; Carmen García-Sánchez; Berta Pascual-Sedano; Alexandre Gironell; Jaime Kulisevsky
Journal:  Mov Disord       Date:  2010-12-15       Impact factor: 10.338

7.  Cognitive correlates of hallucinations and delusions in Parkinson's disease.

Authors:  Stewart A Factor; Michael K Scullin; Ann B Sollinger; Julia O Land; Cathy Wood-Siverio; Lavezza Zanders; Alan Freeman; Donald L Bliwise; William M McDonald; Felicia C Goldstein
Journal:  J Neurol Sci       Date:  2014-10-23       Impact factor: 3.181

8.  Delusional misidentification syndrome and other unusual delusions in advanced Parkinson's disease.

Authors:  Adriana Moro; Renato Puppi Munhoz; Mariana Moscovich; Walter O Arruda; Hélio A G Teive
Journal:  Parkinsonism Relat Disord       Date:  2013-05-14       Impact factor: 4.891

9.  Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease.

Authors:  Antony J Harding; Emily Stimson; Jasmine M Henderson; Glenda M Halliday
Journal:  Brain       Date:  2002-11       Impact factor: 13.501

Review 10.  Epidemiology of psychosis in Parkinson's disease.

Authors:  Gilles Fénelon; Guido Alves
Journal:  J Neurol Sci       Date:  2009-09-08       Impact factor: 3.181

View more
  23 in total

Review 1.  Cognitive decline in Parkinson disease.

Authors:  Dag Aarsland; Byron Creese; Marios Politis; K Ray Chaudhuri; Dominic H Ffytche; Daniel Weintraub; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2017-03-03       Impact factor: 42.937

Review 2.  Minor hallucinations in Parkinson disease: A subtle symptom with major clinical implications.

Authors:  Abhishek Lenka; Javier Pagonabarraga; Pramod Kumar Pal; Helena Bejr-Kasem; Jaime Kulisvesky
Journal:  Neurology       Date:  2019-07-09       Impact factor: 9.910

Review 3.  New Therapeutic Strategies for Lewy Body Dementias.

Authors:  Latha Velayudhan; Dominic Ffytche; Clive Ballard; Dag Aarsland
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09       Impact factor: 5.081

Review 4.  The Neuropsychiatry of Parkinson Disease: A Perfect Storm.

Authors:  Daniel Weintraub; Eugenia Mamikonyan
Journal:  Am J Geriatr Psychiatry       Date:  2019-03-09       Impact factor: 4.105

5.  Progression in Parkinson's Disease: Variation in Motor and Non-motor Symptoms Severity and Predictors of Decline in Cognition, Motor Function, Disability, and Health-Related Quality of Life as Assessed by Two Different Methods.

Authors:  Paulo Bugalho; Filipa Ladeira; Raquel Barbosa; João P Marto; Claudia Borbinha; Laurete da Conceição; Manuel Salavisa; Marlene Saraiva; Bruna Meira; Marco Fernandes
Journal:  Mov Disord Clin Pract       Date:  2021-06-19

6.  Pimavanserin use in a movement disorders clinic: a single-center experience.

Authors:  Abhimanyu Mahajan; Bisena Bulica; Ayesha Ahmad; Patricia Kaminski; Peter LeWitt; Danette Taylor; Shana Krstevska; Neepa Patel
Journal:  Neurol Sci       Date:  2018-07-21       Impact factor: 3.307

Review 7.  The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases.

Authors:  Filippo Baldacci; Sonia Mazzucchi; Alessandra Della Vecchia; Linda Giampietri; Nicola Giannini; Maya Koronyo-Hamaoui; Roberto Ceravolo; Gabriele Siciliano; Ubaldo Bonuccelli; Fanny M Elahi; Andrea Vergallo; Simone Lista; Filippo Sean Giorgi; Harald Hampel
Journal:  Expert Rev Mol Diagn       Date:  2020-02-27       Impact factor: 5.225

8.  Delusions in Parkinson's Disease: A Systematic Review of Published Cases.

Authors:  Nicola Warren; Cullen O'Gorman; Zena Hume; Steve Kisely; Dan Siskind
Journal:  Neuropsychol Rev       Date:  2018-08-02       Impact factor: 7.444

Review 9.  Amyloid-β and Parkinson's disease.

Authors:  Ee Wei Lim; Dag Aarsland; Dominic Ffytche; Raquel Natalia Taddei; Daniel J van Wamelen; Yi-Min Wan; Eng King Tan; Kallol Ray Chaudhuri
Journal:  J Neurol       Date:  2018-10-30       Impact factor: 4.849

10.  Increasing Contrast Improves Object Perception in Parkinson's Disease with Visual Hallucinations.

Authors:  Mirella Díaz-Santos; Zachary A Monge; Robert D Salazar; Grover C Gilmore; Sandy Neargarder; Alice Cronin-Golomb
Journal:  Mov Disord Clin Pract       Date:  2020-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.